ClinicalTrials.gov
ClinicalTrials.gov Menu

EUROpean Pain Audit In Neonates (EUROPAINsurvey)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01694745
Recruitment Status : Completed
First Posted : September 27, 2012
Last Update Posted : January 23, 2014
Sponsor:
Information provided by (Responsible Party):
CARBAJAL, Hôpital Armand Trousseau

Brief Summary:

EUROPAIN Survey is an epidemiological study aimed at assessing current clinical practices regarding the use of sedative and analgesic drugs in newborns admitted to NICUs or PICUs in different countries in Europe. This study is conducted as part of the NeoOpiod study.

The main objective of this study is to determine the current clinical practices regarding the use of sedative and analgesic drugs in newborns in intensive units in different countries in Europe. The principal criteria are: the frequency of ventilated neonates receiving sedation and analgesia, the medications used for sedation and analgesia in ventilated neonates, the length of use of medications administered for sedation and analgesia in ventilated neonates and similarities and differences in sedation and analgesia practices among European countries.

The secondary objectives are: a) to determine the proportion of neonatal units that have developed and implemented local written guidelines to provide continuous sedation and analgesia in ventilated newborn infants as well as to prevent and treat procedural pain, b) to document the published guidelines for neonatal analgesia and sedation in different European countries and develop consensus for common European standards that can be applied in all medical settings, c) to determine the frequency of use of pain assessment tools in ventilated newborn infants and evaluate their impact on pain management practices and d) to determine practices to assess and prevent withdrawal syndromes.

The EUROPAIN STUDY is observational and therefore it will not interfere with routine practices of participating units. No changes in diagnostic, therapeutic or any managing strategy of patients are imposed by the participation in this study. This epidemiological study will only collect data on clinical practices in each unit. It will include all neonates up to a corrected age of 44 weeks post conception.

The maximum duration of data collection for every included infant is 28 days. Data collection will stop before 28 days if the infant leaves the unit (discharge, death, transfer to another hospital). Data will be entered on a secure web-based questionnaire.


Condition or disease
Pain Analgesia Sedation Intesive Care Intratracheal Ventilation

  Show Detailed Description

Study Type : Observational
Actual Enrollment : 6489 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: European Survey of Sedation and Analgesia Practices for Newborns Admitted to Intensive Care Units
Study Start Date : October 2012
Actual Primary Completion Date : June 2013
Actual Study Completion Date : June 2013



Primary Outcome Measures :
  1. The frequency of ventilated neonates receiving sedation and analgesia in different European units [ Time Frame: one year ]

Secondary Outcome Measures :
  1. The medications used for sedation and analgesia in ventilated neonates across Europe [ Time Frame: one year ]
  2. The length of use of medications administered for sedation and analgesia in ventilated neonates [ Time Frame: one year ]
  3. Similarities and differences in sedation and analgesia practices among European countries [ Time Frame: one year ]

Other Outcome Measures:
  1. Variations across European countries of the proportions of units that have developed and implemented local written guidelines for sedation and analgesia in ventilated neonates [ Time Frame: one year ]
  2. Identification and description of national guidelines for sedation and analgesia in neonates in all participating countries. Identification of recommended drugs [ Time Frame: one year ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   up to 45 Weeks   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
  • All neonates up to a corrected age of 44 weeks post conception. That means, for example, that a baby of 40 weeks gestational age can be included up to 28 days (4 weeks) of post natal age or that a baby of 32 weeks gestational age can be included up to 12 weeks of post natal age.
  • The aim of including all neonates is to both ensure a generalization of the findings to all ventilated and non ventilated neonates admitted to intensive care units and to obtain a clear description of practices across Europe.
Criteria

Inclusion Criteria:

  • • All neonates up to a corrected age of 44 weeks post conceptional. That means, for example, that an infant born at 40 weeks gestational age can be included up to 28 days (4 weeks) of post natal age or that a baby of 32 weeks gestational age can be included up to 12 weeks of post natal age.

NOTE: Since this is an observational epidemiological study, all eligible infants of the unit during the study period should be included.

Exclusion Criteria:

  • • The only exclusion criteria of this observational study is the participation of the neonate in a research study including a randomization for the use of sedative or analgesic drugs in ventilated neonates.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01694745


  Show 242 Study Locations
Sponsors and Collaborators
Hôpital Armand Trousseau
Investigators
Principal Investigator: Ricardo Carbajal, MD PhD Armand Trousseau